<![CDATA[Tuberculosis (TB) is an infectious disease requiring long-term treatment using anti-tuberculosis drugs (OAT), which may cause side effects, particularly on blood glucose levels and liver function. This study aimed to analyze blood glucose, ALT, and AST levels and to determine their differences based on treatment duration in category 1 tuberculosis patients during the treatment phase at Baqa Primary Health Center, Samarinda. This study employed an analytical observational design with a cross-sectional approach, involving 30 category 1 tuberculosis patients undergoing 1–2 months of OAT therapy with a rifampicin, isoniazid, pyrazinamide, and ethambutol (RHZE) regimen. Blood glucose was measured using a strip-based glucometer, while ALT and AST were examined using the kinetic method. The Shapiro-Wilk normality test showed that the data were not normally distributed; therefore, the Mann-Whitney test was used to analyze differences. The results showed significant differences in blood glucose (p = 0.032) and ALT (p = 0.003) levels based on treatment duration, whereas no significant difference was found in AST levels (p = 0.099). It is concluded that treatment duration significantly affects blood glucose and ALT levels, but not AST levels. These findings indicate the importance of regularly monitoring blood glucose and liver function, particularly ALT, during OAT therapy to enable early detection of metabolic and hepatotoxic side effects. TB patients are advised to undergo periodic laboratory examinations throughout the treatment period to support therapeutic success.]]>
